Standard

Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study. / Roozeman, Jan-Paul; Mazzinari, Guido; Serpa Neto, Ary et al.

In: Journal of critical care, Vol. 68, 04.2022, p. 31-37.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Roozeman, J-P, Mazzinari, G, Serpa Neto, A, Hollmann, MW, Paulus, F, Schultz, MJ, Pisani, L, Algera, AG, Boers, LS, Bos, LDJ, Botta, M, Dongelmans, DA, Hollmann, MW, Horn, J, Paulus, F, Pillay, J, Schultz, MJ, Neto, AS, Tsonas, AM, Vlaar, APJ, Ahuja, S, van Akkeren, JP, Algoe, CK, van Amstel, RB, Artigas, A, Baur, OL, van de Berg, P, van den Berg, AE, Bergmans, DCJJ, van den Bersselaar, DI, Bertens, FA, Bindels, AJGH, de Boer, MM, den Boer, S, Bogerd, M, Breel, JS, de Bruin, H, de Bruin, S, Bruna, CL, Buiteman-Kruizinga, LA, Cremer, OL, Determann, RM, Dieperink, W, Franke, HS, Galek-Aldridge, MS, de Graaff, MJ, Hagens, LA, Haringman, JJ, van der Heide, ST, van der Heiden, PLJ, Heijnen, NFL, Hiel, SJP, Hoeijmakers, LL, Hol, L, Hoogendoorn, ME, van der Horst, R, Ie, ELK, Ivanov, D, Juffermans, NP, Kho, E, de Klerk, ES, Gemert, AWMMK, Koopmans, M, Kucukcelebi, S, Kuiper, MA, de Lange, DW, van Mourik, N, Nijbroek, SG, Onrust, M, Oostdijk, EAN, Pennartz, CJ, Pisani, L, Purmer, IM, Rettig, TCD, Roozeman, JP, Schuijt, MTU, Sleeswijk, ME, Smit, MR, Spronk, PE, Stilma, W, Strang, AC, The PRoVENT-COVID Collaborative Group, Tuinman, PR, Valk, CMA, Veen-Schra, FL, Veldhuis, LI, Steering Committee:, van Velzen, P, van der Ven, WH, Study coordinators:, van Vliet, P, van der Voort, PHJ, Investigators:, van Welie, L, Wesselink, HJFT, van der Wier-Lubbers, HH, van Wijk, B, Winters, T, Wong, WY & van Zanten, ARH 2022, 'Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study', Journal of critical care, vol. 68, pp. 31-37. https://doi.org/10.1016/j.jcrc.2021.11.009

APA

Vancouver

Author

BibTeX

@article{11e432eb576149f6a0efac9fd59a6b20,
title = "Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study",
abstract = "Background: The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. Methods: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. Results: In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). Conclusions: In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients.",
keywords = "Acute respiratory distress syndrome, COVID-19, Mechanical ventilation, Pulse oximetry, Resource limited settings, SpO/FiO",
author = "Jan-Paul Roozeman and Guido Mazzinari and {Serpa Neto}, Ary and Hollmann, {Markus W.} and Frederique Paulus and Schultz, {Marcus J.} and Luigi Pisani and Algera, {A. G.} and Boers, {L. S.} and Bos, {L. D. J.} and M. Botta and Dongelmans, {D. A.} and Hollmann, {M. W.} and J. Horn and F. Paulus and J. Pillay and Schultz, {M. J.} and Neto, {A. Serpa} and Tsonas, {A. M.} and Vlaar, {A. P. J.} and S. Ahuja and {van Akkeren}, {J. P.} and Algoe, {C. K.} and {van Amstel}, {R. B.} and A. Artigas and Baur, {O. L.} and {van de Berg}, P. and {van den Berg}, {A. E.} and Bergmans, {D. C. J. J.} and {van den Bersselaar}, {D. I.} and Bertens, {F. A.} and Bindels, {A. J. G. H.} and {de Boer}, {M. M.} and {den Boer}, S. and M. Bogerd and Breel, {J. S.} and {de Bruin}, H. and {de Bruin}, S. and Bruna, {C. L.} and Buiteman-Kruizinga, {L. A.} and Cremer, {O. L.} and Determann, {R. M.} and W. Dieperink and Franke, {H. S.} and Galek-Aldridge, {M. S.} and {de Graaff}, {M. J.} and Hagens, {L. A.} and Haringman, {J. J.} and {van der Heide}, {S. T.} and {van der Heiden}, {P. L. J.} and Heijnen, {N. F. L.} and Hiel, {S. J. P.} and Hoeijmakers, {L. L.} and L. Hol and Hoogendoorn, {M. E.} and {van der Horst}, R. and Ie, {E. L. K.} and D. Ivanov and Juffermans, {N. P.} and E. Kho and {de Klerk}, {E. S.} and Gemert, {A. W. M. M. Koopman-van} and M. Koopmans and S. Kucukcelebi and Kuiper, {M. A.} and {de Lange}, {D. W.} and {van Mourik}, N. and Nijbroek, {S. G.} and M. Onrust and Oostdijk, {E. A. N.} and Pennartz, {C. J.} and L. Pisani and Purmer, {I. M.} and Rettig, {T. C. D.} and Roozeman, {J. P.} and Schuijt, {M. T. U.} and Sleeswijk, {M. E.} and Smit, {M. R.} and Spronk, {P. E.} and W. Stilma and Strang, {A. C.} and {The PRoVENT-COVID Collaborative Group} and Tuinman, {P. R.} and Valk, {C. M. A.} and Veen-Schra, {F. L.} and Veldhuis, {L. I.} and {Steering Committee:} and {van Velzen}, P. and {van der Ven}, {W. H.} and {Study coordinators:} and {van Vliet}, P. and {van der Voort}, {P. H. J.} and Investigators: and {van Welie}, L. and Wesselink, {H. J. F. T.} and {van der Wier-Lubbers}, {H. H.} and {van Wijk}, B. and T. Winters and Wong, {W. Y.} and {van Zanten}, {A. R. H.}",
note = "Funding Information: None. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2022",
month = apr,
doi = "10.1016/j.jcrc.2021.11.009",
language = "English",
volume = "68",
pages = "31--37",
journal = "Journal of critical care",
issn = "0883-9441",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Prognostication using SpO2/FiO2 in invasively ventilated ICU patients with ARDS due to COVID-19 - Insights from the PRoVENT-COVID study

AU - Roozeman, Jan-Paul

AU - Mazzinari, Guido

AU - Serpa Neto, Ary

AU - Hollmann, Markus W.

AU - Paulus, Frederique

AU - Schultz, Marcus J.

AU - Pisani, Luigi

AU - Algera, A. G.

AU - Boers, L. S.

AU - Bos, L. D. J.

AU - Botta, M.

AU - Dongelmans, D. A.

AU - Hollmann, M. W.

AU - Horn, J.

AU - Paulus, F.

AU - Pillay, J.

AU - Schultz, M. J.

AU - Neto, A. Serpa

AU - Tsonas, A. M.

AU - Vlaar, A. P. J.

AU - Ahuja, S.

AU - van Akkeren, J. P.

AU - Algoe, C. K.

AU - van Amstel, R. B.

AU - Artigas, A.

AU - Baur, O. L.

AU - van de Berg, P.

AU - van den Berg, A. E.

AU - Bergmans, D. C. J. J.

AU - van den Bersselaar, D. I.

AU - Bertens, F. A.

AU - Bindels, A. J. G. H.

AU - de Boer, M. M.

AU - den Boer, S.

AU - Bogerd, M.

AU - Breel, J. S.

AU - de Bruin, H.

AU - de Bruin, S.

AU - Bruna, C. L.

AU - Buiteman-Kruizinga, L. A.

AU - Cremer, O. L.

AU - Determann, R. M.

AU - Dieperink, W.

AU - Franke, H. S.

AU - Galek-Aldridge, M. S.

AU - de Graaff, M. J.

AU - Hagens, L. A.

AU - Haringman, J. J.

AU - van der Heide, S. T.

AU - van der Heiden, P. L. J.

AU - Heijnen, N. F. L.

AU - Hiel, S. J. P.

AU - Hoeijmakers, L. L.

AU - Hol, L.

AU - Hoogendoorn, M. E.

AU - van der Horst, R.

AU - Ie, E. L. K.

AU - Ivanov, D.

AU - Juffermans, N. P.

AU - Kho, E.

AU - de Klerk, E. S.

AU - Gemert, A. W. M. M. Koopman-van

AU - Koopmans, M.

AU - Kucukcelebi, S.

AU - Kuiper, M. A.

AU - de Lange, D. W.

AU - van Mourik, N.

AU - Nijbroek, S. G.

AU - Onrust, M.

AU - Oostdijk, E. A. N.

AU - Pennartz, C. J.

AU - Pisani, L.

AU - Purmer, I. M.

AU - Rettig, T. C. D.

AU - Roozeman, J. P.

AU - Schuijt, M. T. U.

AU - Sleeswijk, M. E.

AU - Smit, M. R.

AU - Spronk, P. E.

AU - Stilma, W.

AU - Strang, A. C.

AU - The PRoVENT-COVID Collaborative Group

AU - Tuinman, P. R.

AU - Valk, C. M. A.

AU - Veen-Schra, F. L.

AU - Veldhuis, L. I.

AU - Steering Committee:

AU - van Velzen, P.

AU - van der Ven, W. H.

AU - Study coordinators:

AU - van Vliet, P.

AU - van der Voort, P. H. J.

AU - Investigators:

AU - van Welie, L.

AU - Wesselink, H. J. F. T.

AU - van der Wier-Lubbers, H. H.

AU - van Wijk, B.

AU - Winters, T.

AU - Wong, W. Y.

AU - van Zanten, A. R. H.

N1 - Funding Information: None. Publisher Copyright: © 2021 The Authors

PY - 2022/4

Y1 - 2022/4

N2 - Background: The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. Methods: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. Results: In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). Conclusions: In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients.

AB - Background: The SpO2/FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2/FiO2 for mortality in patients with ARDS due to COVID–19. Methods: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID–19. The primary endpoint was 28–day mortality. Results: In 869 invasively ventilated patients, 28–day mortality was 30.1%. The SpO2/FiO2 on day 1 had no prognostic value. The SpO2/FiO2 on day 2 and day 3 had prognostic capacity for death, with the best cut-offs being 179 and 199, respectively. Both SpO2/FiO2 on day 2 (OR, 0.66 [95%–CI 0.46–0.96]) and on day 3 (OR, 0.70 [95%–CI 0.51–0.96]) were associated with 28–day mortality in a model corrected for age, pH, lactate levels and kidney dysfunction (AUROC 0.78 [0.76–0.79]). The measured PaO2/FiO2 and the PaO2/FiO2 calculated from SpO2/FiO2 were strongly correlated (Spearman's r = 0.79). Conclusions: In this cohort of patients with ARDS due to COVID–19, the SpO2/FiO2 on day 2 and day 3 are independently associated with and have prognostic capacity for 28–day mortality. The SpO2/FiO2 is a useful metric for risk stratification in invasively ventilated COVID–19 patients.

KW - Acute respiratory distress syndrome

KW - COVID-19

KW - Mechanical ventilation

KW - Pulse oximetry

KW - Resource limited settings

KW - SpO/FiO

UR - http://www.scopus.com/inward/record.url?scp=85126317579&partnerID=8YFLogxK

U2 - 10.1016/j.jcrc.2021.11.009

DO - 10.1016/j.jcrc.2021.11.009

M3 - Article

C2 - 34872014

VL - 68

SP - 31

EP - 37

JO - Journal of critical care

JF - Journal of critical care

SN - 0883-9441

ER -

ID: 21245227